Gyre Therapeutics/$GYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Ticker

$GYRE
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

579

ISIN

US4037831033
Website
www.gyretx.com

GYRE Metrics

BasicAdvanced
$755M
401.91
$0.02
-
-

Bulls say / Bears say

Gyre Therapeutics has initiated the commercialization of avatrombopag in China as of March 2025, expanding its market presence in liver disease treatments. (gyretx.com)
The company is on track to launch nintedanib in May 2025, potentially increasing revenue streams through its established physician network. (gyretx.com)
Gyre has received IND approval from China's NMPA for a new indication of pirfenidone to treat radiation-induced lung injury, marking its entry into the oncology supportive care space. (gyretx.com)
Revenues for Q1 2025 were $22.1 million, a decrease from $27.2 million in the same period last year, primarily due to a decline in ETUARY sales. (gyretx.com)
The company reported a net income of $3.7 million for Q1 2025, down from $9.9 million in the same period in 2024, indicating a significant decline in profitability. (gyretx.com)
Gyre's general and administrative expenses increased to $5.0 million in Q1 2025 from $3.4 million in the same period in 2024, potentially impacting future profitability. (gyretx.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

GYRE News

AllArticlesVideos
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

GlobeNewsWire·2 weeks ago
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·3 weeks ago
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GYRE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs